JK Moving Services Ranked 4 th Among the Best Places to Work in the DC Region by the Washington Business Journal
JK Moving ranked 4th in the DC region as a Best Place to Work among extra large employers.
'We are honored to be included on the Business Journal's list of Best Places to Work list again. Being ranked so high compared to such large companies speaks to the value we place on attracting and retaining great employees,' said JK Moving Services CEO Chuck Kuhn. 'We focus on creating an outstanding workplace for JK—and its sister companies including CapRelo. Great employees ensure that our customers receive the best service.'
For the 19th year, the Washington Business Journal compiled the region's 75 highest-ranking companies on its annual Best Places to Work survey. JK Moving Services ranked 4th among extra-large employers, up from 7th place last year. Companies are compared to others that have a similar number of locally based employees. Those that were recognized scored highest among hundreds of employers that participated in an employee engagement survey. Best Places to Work results are quantitative, based on survey responses from employees. Each company scored highly by workers for leadership, culture, benefits and more.
JK offers competitive compensation, and for CDL-A long distance drivers, even provides guaranteed annual income, starting at $100,000. The company has great training and ongoing career development; a formal Wellness Program; a generous safe harbor 401(k) and company-paid profit-sharing program; tuition reimbursement; and paid time off. It also provides an Employee Assistance Program; comprehensive medical, dental vision, and ancillary benefit coverages; bonus incentives; and employee volunteer opportunities—including with the JK Community Farm, a nonprofit farm supported by JK Moving that grows and donates fresh produce and protein to the area's food insecure.
In addition, JK is committed to hiring those who have served the nation. The company participates in the SkillBridge Program, which gives active-duty military members who will soon transition into civilian life a chance to gain valuable work experience through specific industry training and development. SkillBridge permits service members to use the last 180 days of their service to train and learn with an industry partner while continuing to receive military compensation and benefits. The company was awarded both a Military Friendly ® Employer and Military Friendly ® Spouse Employer designation.
JK, along with its sister companies CapRelo and JK Land Holdings, employs nearly 1,200 people—a majority of whom live in the Washington, DC metropolitan region. The company has won numerous awards, including being recognized in prior years by the Washington Business Journal as a Best Place to Work and Top Corporate Philanthropist.
ABOUT JK MOVING SERVICES
For more than 40 years, JK Moving Services – the largest independently owned and operated moving company in North America – has provided local, long distance, and global relocation services to a variety of commercial, residential, and government clients. Headquartered in Sterling, Virginia and voted Independent Mover of the Year by the American Trucking Association, the company maintains a full-time, professionally trained staff of relocation and move management experts committed to providing the highest level of customer care. www.JKMoving.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Will your spouse automatically inherit your 401(k)?
It's my understanding that under the Employee Retirement Income Security Act, if a 401(k) participant is married, their spouse is their automatic primary beneficiary. What happens if the participant gets married again but doesn't update the beneficiary to be their new spouse? Does the surviving spouse still automatically override any prior beneficiary designation? Overthinking My 401(k) 'I told him that wouldn't fly': My 90-year-old mother's adviser pushed her to change her beneficiaries. What is going on? Social Security wants to make a change that would cause 3.4 million more people to have to visit its field offices Amazon's stock is falling, as this trend from earnings has investors worried Don't miss: 'He's an egomaniac': My husband said he'll flush his $1.5 million IRA 'down the toilet' rather than split it with me in our divorce. What can I do? Your first spouse will inherit the 401(k) if they remain the beneficiary. The reason is that these accounts become part of your marital property, along with your family home, automobiles, bank and brokerage accounts, and any other assets you acquired during your marriage. It's unlikely, however, that a 401(k) would be ignored during a divorce case. When couples divorce, 401(k) accounts are usually split through a qualified domestic relations order, or QDRO. 'When dividing the assets, the receiving spouse may choose to take the money as a distribution or roll it over into their own retirement plan account, such as an IRA,' says Merrill Edge, an investment advisory service. 'The typical additional tax for early withdrawal does not apply to distributions made pursuant to a QDRO, but the receiving spouse would still owe federal and, if applicable, state income taxes on the distribution,' it adds. 'The decision mainly depends on when the spouse intends to use the money and whether they can wait until retirement.' Rules regarding 401(k)s are set by the Employee Retirement Income Security Act. Here is what the Department of Labor says on the subject: 'In most 401(k) plans and other defined-contribution plans, the plan is written so different protections apply for surviving spouses. In general, in most defined-contribution plans, if you die before you receive your benefits, your surviving spouse will automatically receive them.' But here's the twist for anyone who plans to divorce: 'If you wish to select a different beneficiary, your spouse must consent by signing a waiver, witnessed by a notary or plan representative,' the department adds. 'If you were single when you enrolled in the plan and subsequently married, it is important that you notify your employer and/or plan administrator and change your status under the plan.' Individual retirement accounts are a different kettle of fish. IRAs are unrelated to your employment and deemed separate property, per IRS rules. 'Unlike a 401(k), which requires your spouse to sign off on your naming someone else as the beneficiary, you can leave your IRA to anyone you want,' according to the Gudorf Law Group, which has offices in Ohio. 'Leaving an IRA to a charity, leaving an IRA to your grandchildren — it's entirely up to you. All you have to do is name your intended beneficiary.' And there's another rub for anyone who is remarrying: 'Forgetting to complete or update a beneficiary form is a common mistake,' the law firm adds. 'If you don't have a form on file, some custodians will default to awarding the account to a surviving spouse, but some will make your estate your default beneficiary. This may result in IRA funds going to people you didn't intend, or in adverse tax consequences to your heirs.' But it can get even more complicated than that. In Missouri, for instance, IRAs, Roth IRAs and some 403(b) plans are generally not governed by Erisa, which regulates the administration of employee-based retirement plans, or the Retirement Equity Act, which requires that specific employee-based plans be provided for spouses, according to the Missouri Bar. 'They do not include the same protections for spouses,' lawyers Robert Selsor and Jeffrey Glogower note in this review. 'Thus, an IRA owner may be able to eliminate his or her spouse's right to inherit or make a claim against the IRA without spousal consent. This is true even if a covered plan, such as a 401(k), is rolled into an IRA.' In other words, your ability to disinherit a spouse or former spouse can depend on where you live. In New Jersey, law firm Hanlon Niemann & Wright argues that 401(k)s and IRAs are part of the 'augmented estate,' which refers to the value of a deceased person's assets from which a surviving spouse's elective share is calculated. These assets include the probate estate (mentioned in the will or assets without a named beneficiary) and certain nonprobate transfers. A surviving spouse is entitled to one-third of the deceased spouse's augmented estate. You asked a simple question, but it has a complicated answer. Related: 'I have Type 1 diabetes': I'm 64 with a $1.3 million 401(k). Is it too late for long-term-care insurance? My therapist said he was in-network. My insurance says he's not. Am I obliged to pay out-of-network rates for all prior sessions? Can my husband contest his late brother's $600K will? He experienced oxygen deprivation due to COPD before he died. I have early Alzheimer's and my husband has stage 4 kidney disease. We just inherited $50K. How can this help us? Will your spouse automatically inherit your 401(k)? 10 stocks favored to gain up to 30% in a sector that has missed this year's rally I'm trustee of $65,000 going to my nephew. What are the rules for what I can do with the money? Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
10 hours ago
- Business Upturn
HIMS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Marion Passmore Encourage Investors Who Suffered Losses In Hims To Contact Them To Discuss Their Options If you purchased or acquired securities in Hims between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 02, 2025 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ('Hims & Hers' or the 'Company') (NYSE:HIMS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hims securities between April 29, 2025 and June 23, 2025, both dates inclusive (the 'Class Period'). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Additionally, the Complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material facts, including that: (1) the communication between Hims and the pharmaceutical company Novo Nordisk A/S ('Novo') would facilitate a long-term collaboration that would ensure continued access to the weight-loss drug Wegovy for Hims subscribers; (2) Novo approved of Hims' offerings of compounded semaglutide products under the 'personalization' exception; (3) branded Wegovy would be offered alongside compounded semaglutide options on the Hims platform, thereby expanding user choice; and (4) Defendants made positive statements abou the Novo partnership and Hims users' ongoing access to Wegovy alongside compounded semaglutide products. If you purchased or otherwise acquired Hims & Hers shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit . Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, Walker, Passmore, Esq.(212) 355-4648 [email protected]
Business Insider
a day ago
- Business Insider
MRNA Earnings: Moderna Stock Slumps 10% on Lower Covid Vaccine Demand
Shares in drug giant Moderna (MRNA) plummeted nearly 10% today after it reported a drop in Q2 sales. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The company reported earnings for the period of -$2.13, beating expectations of -$3.03 but also recorded a 41.1% drop in year-over-year sales to $142 million. However, that still beat forecasts of $128.3 million. Sentiment Hit Investor sentiment was also hit by the company dropping its revenue guidance for the full year to $1.85 billion at the midpoint from $2 billion, a 7.5% decrease. It blamed the 'timing of shipments.' The decline was primarily driven by lower Spikevax COVID vaccine sales, which totaled $114 million in the quarter. Moderna said demand is expected to be concentrated in the second half of the year, aligning with the fall and winter seasons as the vaccine continues to transition into a seasonal respiratory product. It also reported 'negligible' RSV vaccine mRESVIA® sales in the second quarter of 2025. The figures continue Moderna's difficult year in comparison with its peers – see below. 'In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine efficacy data and expanded our commercial portfolio with three new U.S. FDA approvals to drive future sales growth,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'Looking forward, we have important catalysts over the next six months across our infectious disease and oncology programs that will help us deliver on the promise of our mRNA platform for patients.' Future Hopes This includes Intismeran autogene, a personalized cancer therapy which is being developed in collaboration with Merck (MRK). This includes two non-small cell lung cancer Phase 3 studies and Phase 2 studies for high-risk muscle invasive and high-risk non-muscle invasive bladder cancer. Cost of sales for 2025 is expected to be approximately $1.2 billion. Full-year 2025 research and development expenses are anticipated to be $3.6 to $3.8 billion, lowered from previous expectations of approximately $4.1 billion. Year-end cash and investments for 2025 are projected to be approximately $6 billion. Recently, Moderna announced an organizational restructuring that will reduce its global workforce by approximately 10%. The company anticipates a total headcount of less than 5,000 by the end of the year. Better news came today for the group after Pfizer (PFE) and its German partner BioNTech (BNTX) lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
